Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Sumedha Sudhaman"'
Autor:
Youjin Oh, Sung Mi Yoon, Jeeyeon Lee, Joo Hee Park, Soowon Lee, Timothy Hong, Liam Il‐young Chung, Sumedha Sudhaman, Timothy Riddell, Charuta C. Palsuledesai, Michael Krainock, Minetta C. Liu, Young Kwang Chae
Publikováno v:
Thoracic Cancer, Vol 15, Iss 13, Pp 1095-1102 (2024)
Abstract Background Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for detection of minimal residual disease (MRD), monitoring treatment response, and early detection of recurrence in cancer patients. In this study
Externí odkaz:
https://doaj.org/article/2756170525d0413ebe1b183d96a92a3b
Autor:
Arash Nabbi, Pengbo Beck, Alberto Delaidelli, Derek A. Oldridge, Sumedha Sudhaman, Kelsey Zhu, S. Y. Cindy Yang, David T. Mulder, Jeffrey P. Bruce, Joseph N. Paulson, Pichai Raman, Yuankun Zhu, Adam C. Resnick, Poul H. Sorensen, Martin Sill, Sebastian Brabetz, Sander Lambo, David Malkin, Pascal D. Johann, Marcel Kool, David T. W. Jones, Stefan M. Pfister, Natalie Jäger, Trevor J. Pugh
Publikováno v:
Genome Medicine, Vol 15, Iss 1, Pp 1-24 (2023)
Abstract Background Cancer immunotherapies including immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR) T-cell therapy have shown variable response rates in paediatric patients highlighting the need to establish robust biomarkers for pa
Externí odkaz:
https://doaj.org/article/55f18503cc5b446bb5969c8df01fb686
Autor:
Emily S. Lebow, Narek Shaverdian, Jordan E. Eichholz, Leah B. Kratochvil, Megan McCune, Yonina R. Murciano-Goroff, Justin Jee, Juliana Eng, Jamie E. Chaft, Mark G. Kris, Ekaterina Kalashnikova, Jordan Feeney, Carly Bess Scalise, Sumedha Sudhaman, Charuta C. Palsuledesai, Meenakshi Malhotra, Michael Krainock, Himanshu Sethi, Alexey Aleshin, Minetta C. Liu, Annemarie F. Shepherd, Abraham J. Wu, Charles B. Simone, Daphna Y. Gelblum, Kaylie A. Johnson, Charles M. Rudin, Daniel R. Gomez, Pedram Razavi, Jorge S. Reis-Filho, James M. Isbell, Bob T. Li, Andreas Rimner
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundSensitive and reliable biomarkers for early detection of recurrence are needed to improve post-definitive radiation risk stratification, disease management, and outcomes for patients with unresectable early-stage or locally advanced non-sma
Externí odkaz:
https://doaj.org/article/3ba4f11343744c078451496fafdf072c
Autor:
Maggie Zhou, Nam Bui, Richa Rathore, Sumedha Sudhaman, Giby V. George, Allyson K. Malashevich, Meenakshi Malhotra, Minetta C. Liu, Alexey Aleshin, Kristen N. Ganjoo
Publikováno v:
Cancers, Vol 15, Iss 1, p 157 (2022)
Background: Leiomyosarcomas (LMS) are aggressive malignancies with a propensity for early relapse. Current surveillance modalities include physical exam and imaging; however, radiological response to therapy may only manifest after 4–6 cycles of tr
Externí odkaz:
https://doaj.org/article/0edd58d19c6d4b028dd3a3a0862915d7
Autor:
Zeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, Sumedha Sudhaman, Turkan Ozturk Topcu, Matt Nichols, Justin Martin, Katherine M. Bui, Charuta C. Palsuledesai, Meenakshi Malhotra, Perry Olshan, Joseph Markowitz, Nikhil I. Khushalani, Ahmad A. Tarhini, Jane L. Messina, Alexey Aleshin
Publikováno v:
Cancer. 129:1723-1734
Autor:
Anirban Das, Uri Tabori, Lauren C. Sambira Nahum, Natalie B. Collins, Rebecca Deyell, Rina Dvir, Cecile Faure-Conter, Timothy E. Hassall, Jane E. Minturn, Melissa Edwards, Elissa Brookes, Vanessa Bianchi, Adrian Levine, Simone C. Stone, Sumedha Sudhaman, Santiago Sanchez-Ramirez, Ayse B. Ercan, Lucie Stengs, Jiil Chung, Logine Negm, Gad Getz, Yosef E. Maruvka, Birgit Ertl-Wagner, Pamela S. Ohashi, Trevor Pugh, Cynthia Hawkins, Eric Bouffet, Daniel A. Morgenstern
Publikováno v:
Clinical Cancer Research.
Purpose: Checkpoint-inhibitors have limited efficacy for children with unselected solid and brain tumors. We report the first prospective pediatric trial (NCT02992964) using nivolumab exclusively for refractory non-hematological cancers harboring tum
Autor:
Uri Tabori, Cynthia E. Hawkins, Pamela S. Ohashi, Trevor J. Pugh, Adam Shlien, Michael D. Taylor, John M. Maris, David Malkin, Carol Durno, Melyssa Aronson, Daniel A. Morgenstern, Eric Bouffet, Gary Mason, David Samuel, Sangeetha N. Kalimuthu, Lazar Joksimovic, Michal Zapotocky, Matthew Zatzman, A. Sorana Morrissy, Liana Nobre, Nuno M. Nunes, Martin Komosa, Robert Siddaway, Sumedha Sudhaman, Melissa Edwards, Alexandra N. Riemenschneider, Simone C. Stone, Melissa A. Galati, Brittany B. Campbell
The RAS/MAPK pathway is an emerging targeted pathway across a spectrum of both adult and pediatric cancers. Typically, this is associated with a single, well-characterized point mutation in an oncogene. Hypermutant tumors that harbor many somatic mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12d3bf160d0420590ae5aee6609ebe89
https://doi.org/10.1158/2159-8290.c.6549365.v1
https://doi.org/10.1158/2159-8290.c.6549365.v1
Autor:
Uri Tabori, Cynthia E. Hawkins, Pamela S. Ohashi, Trevor J. Pugh, Adam Shlien, Michael D. Taylor, John M. Maris, David Malkin, Carol Durno, Melyssa Aronson, Daniel A. Morgenstern, Eric Bouffet, Gary Mason, David Samuel, Sangeetha N. Kalimuthu, Lazar Joksimovic, Michal Zapotocky, Matthew Zatzman, A. Sorana Morrissy, Liana Nobre, Nuno M. Nunes, Martin Komosa, Robert Siddaway, Sumedha Sudhaman, Melissa Edwards, Alexandra N. Riemenschneider, Simone C. Stone, Melissa A. Galati, Brittany B. Campbell
Table S1: Summary of likely pathogenic mutations detected in Foundation Medicine cohort of 1215 pediatric cancers. Table S2: Summary of RAS/MAPK pathway mutations and consequences detected in 48 RRD cancers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1031a84e4fc1653137656aec9d2eb951
https://doi.org/10.1158/2159-8290.22540376
https://doi.org/10.1158/2159-8290.22540376
Autor:
Uri Tabori, Zachary F. Pursell, Cynthia J. Guidos, Cynthia E. Hawkins, James G. Jackson, Zucai Suo, Eric Bouffet, Adam Shlien, Alberto Martin, Carol Durno, Oz Mordechai, Jonathan N. Byrd, Gavin P. Dunn, Tomasz Sarosiek, Andrea Seeley, Jagadeesh Ramdas, Xia Wang, Melyssa Aronson, Nuno M. Nunes, Victoria J. Forster, Jiil Chung, Dana Elshaer, Richard de Borja, Melissa Edwards, Robert Siddaway, Iram Siddiqui, Lazar Joksimovic, Ayse B. Ercan, Vivian S. Park, Nathan A. Ungerleider, Walter J. Zahurancik, Taylor Bridge, Sumedha Sudhaman, Miki S. Gams, Karl P. Hodel, Melissa A. Galati
Supplementary Figure S1 (related to Figure 1): PoleP286R mouse model design, validation, and tumor findings. Supplementary Figure S2 (related to Figure 1): PoleS459F mouse model design, validation, and tumor findings. Supplementary Figure S3 (related
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be86ccbe1dd1695c7f2fa2cfc56c0fe6
https://doi.org/10.1158/0008-5472.22427518.v1
https://doi.org/10.1158/0008-5472.22427518.v1
Autor:
Uri Tabori, Zachary F. Pursell, Cynthia J. Guidos, Cynthia E. Hawkins, James G. Jackson, Zucai Suo, Eric Bouffet, Adam Shlien, Alberto Martin, Carol Durno, Oz Mordechai, Jonathan N. Byrd, Gavin P. Dunn, Tomasz Sarosiek, Andrea Seeley, Jagadeesh Ramdas, Xia Wang, Melyssa Aronson, Nuno M. Nunes, Victoria J. Forster, Jiil Chung, Dana Elshaer, Richard de Borja, Melissa Edwards, Robert Siddaway, Iram Siddiqui, Lazar Joksimovic, Ayse B. Ercan, Vivian S. Park, Nathan A. Ungerleider, Walter J. Zahurancik, Taylor Bridge, Sumedha Sudhaman, Miki S. Gams, Karl P. Hodel, Melissa A. Galati
POLE mutations are a major cause of hypermutant cancers, yet questions remain regarding mechanisms of tumorigenesis, genotype–phenotype correlation, and therapeutic considerations. In this study, we establish mouse models harboring cancer-associate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b21c938f653fba762197235f84abd90d
https://doi.org/10.1158/0008-5472.c.6512707.v1
https://doi.org/10.1158/0008-5472.c.6512707.v1